Biohaven

BHVN · NYSE

$11.81+$0.46 (+4.05%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $11.35

Latest news

NewsOct 8, 12:11 PM ETVandana Singh
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Press releaseOct 8, 4:00 AM ETPRNewswire
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Press releaseSep 28, 7:30 AM ETPRNewswire
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
NewsSep 18, 8:01 AM ETAvi Kapoor
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
NewsSep 18, 4:25 AM ETAvi Kapoor
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Press releaseSep 11, 6:28 PM ETPRNewswire
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
NewsSep 10, 1:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsSep 10, 10:43 AM ETVandana Singh
FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
NewsSep 10, 8:06 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsSep 10, 6:33 AM ET
Biohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026
NewsAug 26, 1:41 PM ETVandana Singh
Why Is Biohaven Stock Soaring Wednesday?
NewsAug 26, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseAug 26, 2:36 AM ETPRNewswire
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Press releaseAug 25, 4:41 PM ETPRNewswire
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
Press releaseAug 10, 4:02 PM ETPRNewswire
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
Press releaseAug 6, 7:00 AM ETPRNewswire
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Press releaseJul 27, 7:00 AM ETPRNewswire
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
Press releaseJul 20, 7:30 AM ETPRNewswire
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
NewsJul 17, 10:09 AM ETAvi Kapoor
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
Press releaseJul 9, 5:00 PM ETPRNewswire
Biohaven Announces Scientific Leadership Transitions
Press releaseJun 30, 7:30 AM ETPRNewswire
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
NewsJun 29, 2:04 PM ETVandana Singh
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
Press releaseJun 29, 7:30 AM ETPRNewswire
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Press releaseJun 1, 7:30 AM ETPRNewswire
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
Press releaseMay 27, 7:30 AM ETPRNewswire
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
Press releaseMay 26, 7:30 AM ETPRNewswire
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
Press releaseMay 4, 4:02 PM ETPRNewswire
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Press releaseMar 19, 7:30 AM ETPRNewswire
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
NewsMar 9, 11:47 AM ETVandana Singh
What's Going On With Biohaven Stock On Monday?
Press releaseMar 2, 4:05 PM ETPRNewswire
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
Press releaseJan 12, 11:15 AM ETPRNewswire
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
NewsJan 9, 12:35 PM ET
10 Health Care Stocks Whale Activity In Today's Session
Press releaseJan 7, 7:00 AM ETPRNewswire
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
NewsJan 2, 8:02 AM ETAvi Kapoor
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session
NewsDec 26, 9:45 AM ETAvi Kapoor
US Stocks Mixed; Biohaven Shares Fall
NewsDec 26, 9:26 AM ETRishabh Mishra
Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED)
NewsDec 26, 8:20 AM ETVandana Singh
Biohaven Misses The Mark In Depression Trial, Stock Falls
NewsNov 12, 8:10 AM ETAvi Kapoor
FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
NewsNov 12, 4:42 AM ETAvi Kapoor
Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
NewsNov 5, 12:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsNov 5, 12:05 PM ETAvi Kapoor
Crude Oil Down 1%; Solid Power Shares Spike Higher
NewsNov 5, 10:19 AM ETAvi Kapoor
Dow Surges 100 Points; McDonald's Posts Downbeat Earnings
NewsNov 3, 8:14 AM ETAvi Kapoor
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

12 Health Care Stocks Moving In Thursday's Intraday Session

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Biohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026

Why Is Biohaven Stock Soaring Wednesday?

12 Health Care Stocks Moving In Wednesday's Intraday Session

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results

Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday

Biohaven Announces Scientific Leadership Transitions

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

What's Going On With Biohaven Stock On Monday?

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

10 Health Care Stocks Whale Activity In Today's Session

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

US Stocks Mixed; Biohaven Shares Fall

Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED)

Biohaven Misses The Mark In Depression Trial, Stock Falls

FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Wednesday's Intraday Session

Crude Oil Down 1%; Solid Power Shares Spike Higher

Dow Surges 100 Points; McDonald's Posts Downbeat Earnings

Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session